Open Access

Monoclonal anti‑MUC1 antibody with novel octahydropyrazino[2,1‑a:5,4‑a']diisoquinoline derivative as a potential multi‑targeted strategy in MCF‑7 breast cancer cells

  • Authors:
    • Agnieszka Gornowicz
    • Wojciech Szymanowski
    • Anna Bielawska
    • Anna Szymanowska
    • Robert Czarnomysy
    • Zbigniew Kałuża
    • Krzysztof Bielawski
  • View Affiliations

  • Published online on: August 2, 2019     https://doi.org/10.3892/or.2019.7256
  • Pages: 1391-1403
  • Copyright: © Gornowicz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to examine the multi‑targeted potential of a monoclonal antibody against mucin‑1 (MUC1) and novel octahydropyrazin[2,1‑a:5,4‑a']diisoquinoline derivative (OM‑86II) in estrogen receptor‑positive MCF‑7 human breast cancer cells. The cell viability was measured by an MTT assay. The analyses of cell cycle and disruption of mitochondrial membrane potential were performed by flow cytometry. Fluorescent microscopy and flow cytometry were used to demonstrate the effect of the compounds on apoptosis. ELISA was conducted to check the concentrations of proteins involved in multiple intracellular signaling pathways, responsible for the promotion of tumor growth and breast cancer progression, namely matrix metalloproteinase (MMP)‑2, matrix MMP‑9, tumor necrosis factor‑α (TNF‑α), cyclooxygenase‑2 (COX‑2), soluble intercellular adhesion molecule 1 (sICAM1) and mTOR. The combination therapy based on anti‑MUC1 antibody and novel OM‑86II inhibited the proliferation of MCF‑7 breast cancer cells. Its inhibitory effects were associated with the induction of cell cycle arrest and apoptosis. It was demonstrated that anti‑MUC1 antibody with OM‑86II decreased the concentrations of MMP‑2, MMP‑9, sICAM1 and mTOR. In addition, the combined therapy exhibited anti‑inflammatory activity, which was demonstrated by a decrease in TNF‑α and COX‑2 concentrations. The present data provided evidence that the combination of anti‑MUC1 antibody with novel OM‑86II represents a multi‑targeted strategy in MCF‑7 breast cancer treatment.

Related Articles

Journal Cover

October 2019
Volume 42 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gornowicz, A., Szymanowski, W., Bielawska, A., Szymanowska, A., Czarnomysy, R., Kałuża, Z., & Bielawski, K. (2019). Monoclonal anti‑MUC1 antibody with novel octahydropyrazino[2,1‑a:5,4‑a']diisoquinoline derivative as a potential multi‑targeted strategy in MCF‑7 breast cancer cells. Oncology Reports, 42, 1391-1403. https://doi.org/10.3892/or.2019.7256
MLA
Gornowicz, A., Szymanowski, W., Bielawska, A., Szymanowska, A., Czarnomysy, R., Kałuża, Z., Bielawski, K."Monoclonal anti‑MUC1 antibody with novel octahydropyrazino[2,1‑a:5,4‑a']diisoquinoline derivative as a potential multi‑targeted strategy in MCF‑7 breast cancer cells". Oncology Reports 42.4 (2019): 1391-1403.
Chicago
Gornowicz, A., Szymanowski, W., Bielawska, A., Szymanowska, A., Czarnomysy, R., Kałuża, Z., Bielawski, K."Monoclonal anti‑MUC1 antibody with novel octahydropyrazino[2,1‑a:5,4‑a']diisoquinoline derivative as a potential multi‑targeted strategy in MCF‑7 breast cancer cells". Oncology Reports 42, no. 4 (2019): 1391-1403. https://doi.org/10.3892/or.2019.7256